Orchestra BioMed Holdings announced its participation in the Jefferies Global Healthcare Conference on June 4, 2026, where CEO David Hochman will discuss the company's progress in pivotal clinical trials for its flagship therapies. The company is advancing two main products: AVIM Therapy for hypertension, developed in partnership with Medtronic, and Virtue SAB, a novel drug delivery balloon for artery disease. Both products have received FDA Breakthrough Device Designations, signaling their potential impact on large global markets. The event will include a live webcast and investor meetings, underscoring Orchestra BioMed's strategic collaborations and upcoming milestones in healthcare innovation.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
